Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.82 EUR | +1.61% | +5.40% | +10.90% |
04-10 | Aegon: successful placement of bond issue | CF |
04-10 | Aegon Prices $760 Million Note for General Corporate Purposes | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Its low valuation, with P/E ratio at 8.94 and 6.88 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.90% | 10.89B | A | ||
+14.78% | 79.51B | B- | ||
+6.49% | 50.22B | B+ | ||
+1.35% | 48.11B | B | ||
+9.53% | 42.2B | B+ | ||
+6.55% | 39.71B | B+ | ||
+19.34% | 37.78B | B | ||
+2.84% | 30.07B | B | ||
-7.77% | 27.56B | B- | ||
-18.42% | 24.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AGN Stock
- AGN Stock
- Ratings Aegon N.V.